Expression of Human β3GalT5-1 in Insect Cells as Active Glycoforms for the Efficient Synthesis of Cancer-Associated

Chih-Chuan Kung1, Jennifer M Lo1, Kuo-Shiang Liao1

  • 1Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.

Insights

Researchers engineered a human enzyme, beta3GalT5-1, to efficiently synthesize globo-series glycans, crucial targets in cancer therapy. This engineered enzyme is 10-fold more effective than previous methods for producing these cancer-targeting molecules.

Area of Science:

  • Glycobiology
  • Enzymology
  • Cancer Therapeutics

Background:

  • Globo-series glycosphingolipids (GSLs) are cell surface markers found on various cancers, making them targets for cancer vaccines and therapeutics.
  • Current enzymatic synthesis of globo-series glycans, particularly the conversion of Gb4 to Gb5 (SSEA-3), using microbial galactosyltransferase LgtD, is inefficient.

Purpose of the Study:

  • To enhance the efficiency of globo-series glycan synthesis by exploring human galactosyltransferases.
  • To identify and engineer a highly efficient human enzyme for the synthesis of globo-series glycans for cancer therapeutic development.

Main Methods:

  • Screened human beta-1,3-galactosyltransferase (β3GalT5) isozymes (1 and 2) for improved Gb4 to Gb5 conversion efficiency.
  • Evaluated activity and substrate specificity of different glycoforms of a common soluble domain of β3GalT5.
  • Utilized site-specific alanine scanning to identify a highly active variant (S66A β3GalT5).
  • Determined the X-ray structure of β3GalT5-1 for molecular modeling and mechanistic insights.

Main Results:

  • Human β3GalT5 isozyme 1 (β3GalT5-1) demonstrated higher activity than isozyme 2 (β3GalT5-2) in the synthesis of globo-series glycans.
  • A S66A variant of β3GalT5-1 was identified with a 10-fold increase in efficiency compared to the microbial LgtD.
  • Structural and kinetic analyses provided rationale for the enhanced catalytic efficiency of the engineered enzyme.

Conclusions:

  • Engineered human β3GalT5-1 (S66A variant) offers a significantly more efficient enzymatic method for synthesizing globo-series glycans.
  • This improved synthesis provides a valuable tool for the development of novel cancer vaccines and therapeutics targeting GSLs.

Related Concept Videos

Oligosaccharide Assembly01:24

Oligosaccharide Assembly

Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
2.7K